» Articles » PMID: 38002844

Noninvasive Monitoring Strategies for Bronchopulmonary Dysplasia or Post-Prematurity Respiratory Disease: Current Challenges and Future Prospects

Overview
Specialty Health Services
Date 2023 Nov 25
PMID 38002844
Authors
Affiliations
Soon will be listed here.
Abstract

Definitions of bronchopulmonary dysplasia (BPD) or post-prematurity respiratory disease (PPRD) aim to stratify the risk of mortality and morbidity, with an emphasis on long-term respiratory outcomes. There is no univocal classification of BPD due to its complex multifactorial nature and the substantial heterogeneity of clinical presentation. Currently, there is no definitive treatment available for extremely premature very-low-birth-weight infants with BPD, and challenges in finding targeted preventive therapies persist. However, innovative stem cell-based postnatal therapies targeting BPD-free survival are emerging, which are likely to be offered in the first few days of life to high-risk premature infants. Hence, we need easy-to-use noninvasive tools for a standardized, precise, and reliable BPD assessment at a very early stage, to support clinical decision-making and to predict the response to treatment. In this non-systematic review, we present an overview of strategies for monitoring preterm infants with early and evolving BPD-PPRD, and we make some remarks on future prospects, with a focus on near-infrared spectroscopy (NIRS).

Citing Articles

Safety, Efficacy and Bio-Distribution Analysis of Exosomes Derived From Human Umbilical Cord Mesenchymal Stem Cells for Effective Treatment of Bronchopulmonary Dysplasia by Intranasal Administration in Mice Model.

Xu W, Jieda X, Wu Y, Du F, Ma L, Luo L Int J Nanomedicine. 2025; 20:2521-2553.

PMID: 40034220 PMC: 11874997. DOI: 10.2147/IJN.S501843.


Guidelines for the use of lung ultrasound to optimise the management of neonatal respiratory distress: international expert consensus.

Liu J, Inchingolo R, Suryawanshi P, Guo B, Kurepa D, Cortes R BMC Med. 2025; 23(1):114.

PMID: 39988689 PMC: 11849336. DOI: 10.1186/s12916-025-03879-5.

References
1.
NORTHWAY Jr W, ROSAN R, Porter D . Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia. N Engl J Med. 1967; 276(7):357-68. DOI: 10.1056/NEJM196702162760701. View

2.
Yu Z, Wang L, Wang Y, Zhang M, Xu Y, Liu A . Development and Validation of a Risk Scoring Tool for Bronchopulmonary Dysplasia in Preterm Infants Based on a Systematic Review and Meta-Analysis. Healthcare (Basel). 2023; 11(5). PMC: 10000930. DOI: 10.3390/healthcare11050778. View

3.
Bancalari E, Jain D . Bronchopulmonary Dysplasia: 50 Years after the Original Description. Neonatology. 2019; 115(4):384-391. DOI: 10.1159/000497422. View

4.
Pinti P, Tachtsidis I, Hamilton A, Hirsch J, Aichelburg C, Gilbert S . The present and future use of functional near-infrared spectroscopy (fNIRS) for cognitive neuroscience. Ann N Y Acad Sci. 2018; 1464(1):5-29. PMC: 6367070. DOI: 10.1111/nyas.13948. View

5.
Bertini G, Coviello C, Gozzini E, Bianconi T, Bresci C, Leonardi V . Change of Cerebral Oxygenation during Surfactant Treatment in Preterm Infants: "LISA" versus "InSurE" Procedures. Neuropediatrics. 2017; 48(2):98-103. DOI: 10.1055/s-0037-1598647. View